Author:
Wu Zheng,Gabrielson Andrew,Hwang Jimmy J.,Pishvaian Michael J.,Weiner Louis M.,Zhuang Tingting,Ley Lisa,Marshall John L.,He Aiwu Ruth
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference26 articles.
1. Jemal A, Siegel R, Xu J et al (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300
2. Burris HA III, Moore MJ, Anderson J et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413
3. Von Hoff DD, Ervin T, Arena FP, et al (2013) Final results of a randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas. ASCO Gastrointestinal Cancers Symposium, Abstract LBA 148
4. Conroy T, Desseigne F, Ychou M et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817–1825
5. Pelzer U, Kubica K, Stieler J, et al (2008) A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. J Clin Oncol 26: suppl abstr 4508
Cited by
44 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献